APG vs EXPD

The Advanced Deterministic Scorecard reveals a weak financial health profile with a Piotroski F-Score of 4/9, indicating borderline stability, and a missing Altman Z-Score prevents a full solvency assessment. Despite strong recent price performance and robust revenue and earnings growth, the stock trades at a steep valuation (P/E of 116.19 vs. sector average of 48.97) far above its Graham Number of $7.99 and intrinsic value of $10.62, suggesting significant overvaluation. Earnings quality is deteriorating, with 3 of the last 4 quarters missing estimates by an average of -32.33%, and YoY EPS has declined by 41.2% despite positive Q/Q growth. Heavy insider selling of $20.69M in the last 6 months and a bearish technical trend further reinforce caution.

EXPD exhibits exceptional operational health with a Piotroski F-Score of 8/9 and a very conservative debt profile (Debt/Equity 0.24). However, the stock is severely overvalued, trading at $147.56—nearly 3x its Graham Number ($48.53) and 3.5x its Intrinsic Value ($41.65). This valuation gap is exacerbated by negative YoY revenue (-3.30%) and earnings growth (-11.50%), alongside a high PEG ratio of 3.80. With bearish insider selling and a 0/100 technical trend, the current price appears unsustainable relative to fundamental growth.